Registry for Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease
(IPF/ILD-PRO Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial gathers information on idiopathic pulmonary fibrosis (a lung disease that causes scarring and breathing issues) and other similar lung diseases. The main goal is to understand how these diseases progress, how they affect daily life, and what treatments people use. Participants provide blood samples (venipuncture or phlebotomy), answer questions about their health, and undergo chest imaging for research. This trial suits those recently diagnosed with idiopathic pulmonary fibrosis or another chronic lung condition that has worsened over the past two years. As an unphased trial, it offers participants the opportunity to contribute to a deeper understanding of their condition and potentially improve future treatments.
Do I need to stop my current medications to join the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Why are researchers excited about this trial?
Researchers are excited about this trial because it aims to gather comprehensive data on idiopathic pulmonary fibrosis (IPF) and interstitial lung disease (ILD) through blood samples, detailed data collection, and high-resolution CT images. Unlike current treatments that focus primarily on symptom management or slowing disease progression, this registry could uncover new insights into the diseases' progression and potential new targets for therapy. By collecting and analyzing this wealth of information, researchers hope to identify patterns and factors that could lead to more effective treatments in the future.
Who Is on the Research Team?
Scott Palmer, MD
Principal Investigator
Duke Clinical Research Institute, Duke University
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Enrollment
Participants with IPF and other chronic fibrosing ILDs are enrolled in the registry
Data Collection
Data and samples are collected from participants to study the natural history, healthcare interactions, and quality of life
Follow-up
Participants are monitored for safety and effectiveness after data collection
What Are the Treatments Tested in This Trial?
Interventions
- Blood Sample Collection
- Data Collection
- HRCT Image Collection
Find a Clinic Near You
Who Is Running the Clinical Trial?
Duke University
Lead Sponsor
Boehringer Ingelheim
Industry Sponsor